Psyence Group Inc. is a Canadian life science biotechnology company specializing in the research, cultivation, and production of natural psychedelics and nature-based compounds aimed primarily at mental health applications. Founded in 2019 and headquartered in Toronto, the company operates one of the first federally licensed commercial psilocybin cultivation and production facilities certified to ISO22000 standards. Psyence Group focuses particularly on developing natural psilocybin products and medicinal formulations targeting anxiety, depression, and related conditions within the context of palliative care. The company's work integrates neurological and pharmaceutical expertise to innovate safe and effective psychedelic treatments and protocols in clinical environments. Psyence also produces functional mushroom wellness products derived from adaptogenic fungi traditionally used for stress relief and general well-being. Its operations extend globally, supported by a broad scientific and medical team, and it is listed on international markets including the Frankfurt Stock Exchange. The company plays a pioneering role in advancing psychedelic-based therapeutic solutions informed by both nature and science.